CARDIOVASCULAR MEDICINE

Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life

C J Malkin¹, P J Pugh¹, P D Morris¹, K E Kerry², R D Jones², T H Jones^2,* and K S Channer¹

¹ Department of Cardiology, Royal Hallamshire Hospital, Sheffield S10 2JF, UK
² Academic Unit of Endocrinology, Hormone and Vascular Biology Group, Division of Genomic Medicine, University of Sheffield, Sheffield, UK

Correspondence to:
Correspondence to:
Dr K S Channer
M131, Cardiology, Royal Hallamshire Hospital, Glossop Road, Sheffield S10 2JF, UK; email: kevin.channer{at}sth.nhs.uk

Background: Low serum testosterone is associated with several cardiovascular risk factors including dyslipidaemia, adverse clotting profiles, obesity, and insulin resistance. Testosterone has been reported to improve symptoms of angina and delay time to ischaemic threshold in unselected men with coronary disease.

Objective: This randomised single blind placebo controlled crossover study compared testosterone replacement therapy (Sustanon 100) with placebo in 10 men with ischaemic heart disease and hypogonadism.

Results: Baseline total testosterone and bioavailable testosterone were respectively 4.2 (0.5) nmol/l and 1.7 (0.4) nmol/l. After a month of testosterone, delta value analysis between testosterone and placebo phase showed that mean (SD) trough testosterone concentrations increased significantly by 4.8 (6.6) nmol/l (total testosterone) (p = 0.05) and 3.8 (4.5) nmol/l (bioavailable testosterone) (p = 0.025), time to 1 mm ST segment depression assessed by Bruce protocol exercise treadmill testing increased by 74 (54) seconds (p = 0.002), and mood scores assessed with validated questionnaires all improved. Compared with placebo, testosterone therapy was also associated with a significant reduction of total cholesterol and serum tumour necrosis factor with delta values of –0.41 (0.54) mmol/l (p = 0.04) and –1.8 (2.4) pg/ml (p = 0.05) respectively.

Conclusion: Testosterone replacement therapy in hypogonadal men delays time to ischaemia, improves mood, and is associated with potentially beneficial reductions of total cholesterol and serum tumour necrosis factor .

Abbreviations: ELISA, enzyme linked immunosorbent assay; HDL, high density lipoprotein; LDL, low density lipoprotein; PSA, prostate specific antigen; TNF, tumour necrosis factor

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Wald, M., Miner, M., Seftel, A. D. (2008). State of the Art Reviews: Male Menopause: Fact or Fiction?. AMERICAN JOURNAL OF LIFESTYLE MEDICINE 2: 132-141 [Abstract]  
• Haddad, R. M., Kennedy, C. C., Caples, S. M., Tracz, M. J., Bolona, E. R., Sideras, K., Uraga, M. V., Erwin, P. J., Montori, V. M. (2007). Testosterone and Cardiovascular Risk in Men: A Systematic Review and Meta-analysis of Randomized Placebo-Controlled Trials. Mayo Clin Proc. 82: 29-39 [Abstract] [Full Text]  
• Solomon, A M, Bouloux, P M G (2006). Modifying muscle mass - the endocrine perspective.. J Endocrinol 191: 349-360 [Abstract] [Full Text]  
• Ding, E. L., Song, Y., Malik, V. S., Liu, S. (2006). Sex Differences of Endogenous Sex Hormones and Risk of Type 2 Diabetes: A Systematic Review and Meta-analysis. JAMA 295: 1288-1299 [Abstract] [Full Text]  
• Nieschlag, E., Behre, H.M., Bouchard, P., Corrales, J.J., Jones, T.H., Stalla, G.K., Webb, S.M., Wu, F.C.W. (2004). Testosterone replacement therapy: current trends and future directions. Hum Reprod Update 10: 409-419 [Abstract] [Full Text]